Imprimis Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.11.18	IMMY Turning Heads, HSM Awaits Phase 3 Data This Year, LQDA On Watch (RTTNews)
26.10.18	FATE Catches Eyes, LJPC Upbeat, CLSD To Submit XIPERE NDA By Year-end (RTTNews)
25.10.18	Eyes On Imprimis... (RTTNews)
30.05.18	ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery (PR Newswire)
15.05.18	Imprimis Pharmaceuticals Announces First Quarter 2018 Results (PR Newswire)
15.05.18	Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners (PR Newswire)
10.04.18	Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract &... (PR Newswire)
30.03.18	River Rock Entertainment Authority Enters into Support Agreements with Holders of its Outstanding Indenture Indebtedness and Commitment to Fund the Related Settlements (PR Newswire)
27.03.18	Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation (PR Newswire)
08.03.18	Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results (PR Newswire)
07.03.18	Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018 (PR Newswire)
06.03.18	Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations (PR Newswire)
15.02.18	Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST (PR Newswire)
30.01.18	Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List (PR Newswire)
24.01.18	Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility (PR Newswire)
10.01.18	LIONSGATE TO RELEASE FISCAL 2018 THIRD QUARTER EARNINGS AND HOLD ANALYST AND INVESTOR CONFERENCE CALL AFTER MARKET CLOSE ON THURSDAY, FEBRUARY 8 (PR Newswire)
06.12.17	The Department of Defense Awards Terumo BCT Grant to Explore Feasibility of Next-Generation Mirasol (PR Newswire)
14.11.17	Imprimis Pharmaceuticals Announces Third Quarter 2017 Results (PR Newswire)
31.10.17	Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST (PR Newswire)
24.10.17	Imprimis Launches Surface Pharmaceuticals Subsidiary (PR Newswire)
19.10.17	Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis® (PR Newswire)
02.10.17	Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations (PR Newswire)
14.09.17	FDA Curcumin Investigation Supports Imprimis Statement (PR Newswire)
05.09.17	Biocept Launches Liquid Biopsy Test for NRAS Mutations (PR Newswire)
07.08.17	Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice (PR Newswire)
27.07.17	Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone (PR Newswire)
20.07.17	Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings (PR Newswire)
29.06.17	Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets (PR Newswire)
23.06.17	Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer and Director (PR Newswire)
20.06.17	Eton Pharmaceuticals Announces $20 Million Series A Financing (PR Newswire)
10.05.17	Imprimis Pharmaceuticals Announces First Quarter 2017 Financial Results (PR Newswire)
04.05.17	Imprimis Pharmaceuticals to Launch its Simple Drops™ Combination Glaucoma Drops at Leading Cataract & Refractive Surgery Medical Meeting (PR Newswire)
02.05.17	Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears™ (PR Newswire)
18.04.17	Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis' Ophthalmic Portfolio Market Opportunity in the U.S. Midwest (PR Newswire)
06.04.17	Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease (PR Newswire)
29.03.17	Gainers & Losers Of Mar.28: CBIO, AKER, IMMY, HTGM, PAVM... (RTTNews)
28.03.17	Gainers & Losers Of Mar.27: APOP, IPXL, ZIOP, FOMX... (RTTNews)
22.03.17	Imprimis Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering (PR Newswire)
21.03.17	Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results (PR Newswire)
20.03.17	Peer-Reviewed Paper Demonstrates the Benefits of Dropless Cataract Surgery® (PR Newswire)
07.03.17	Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2016 Financial Report Conference Call and Webcast on March 21, 2017 at 4:30 p.m. EDT (PR Newswire)
17.02.17	Gainers & Losers Of The Day: CRSP, XTLB, CRSP, ACUR, EVOK... (RTTNews)
16.02.17	Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility (PR Newswire)
21.12.16	Imprimis Pharmaceuticals and FocusScript Partner to Exclusively Offer the Correct Compound™ Program (PR Newswire)
19.12.16	Imprimis Pharmaceuticals Announces $9.8 Million Private Placement of Units (PR Newswire)
01.12.15	Express Scripts Champions $1 Per Pill Access To Alternative For Daraprim (RTTNews)
02.12.14	Imprimis To Acquire South Coast Specialty Compounding Inc - Quick Facts (RTTNews)
28.08.13	Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity (PR Newswire)
12.08.13	Imprimis Pharmaceuticals, Inc. Comments on Delay in Phase III Impracor™ Program (PR Newswire)
05.08.13	Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Imprimis Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten